Currently, there are 150.83M common shares owned by the public and among those 118.97M shares have been available to trade.
The company’s stock has a 5-day price change of -43.53% and -63.57% over the past three months. OPTN shares are trading -73.74% year to date (YTD), with the 12-month market performance down to -72.90% lower. It has a 12-month low price of $0.38 and touched a high of $2.10 over the same period. OPTN has an average intraday trading volume of 496.74K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -47.98%, -52.35%, and -68.64% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of OptiNose Inc (NASDAQ: OPTN) shares accounts for 62.44% of the company’s 150.83M shares outstanding.
It has a market capitalization of $51.10M and a beta (3y monthly) value of -0.15. The earnings-per-share (ttm) stands at -$0.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.89% over the week and 10.27% over the month.
Earnings per share for the fiscal year are expected to increase by 35.28%, and 56.89% over the next financial year.
Looking at the support for the OPTN, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on March 11, 2024, with the firm’s price target at $5. Lake Street coverage for the OptiNose Inc (OPTN) stock in a research note released on August 21, 2023 offered a Buy rating with a price target of $3. Jefferies was of a view on October 21, 2022 that the stock is Buy, while RBC Capital Mkts gave the stock Outperform rating on April 07, 2021, issuing a price target of $17. Cowen on their part issued Outperform rating on December 18, 2019.
